Actively Recruiting
Study of Feminizing Hormone Treatment Effects in Transgender Women Starting at Age 18
Led by Odense University Hospital · Updated on 2025-03-21
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the effects of feminizing hormone treatment on cardiovascular health in transgender women and non-binary persons. This observational cohort study will follow 100 participants who are starting gender affirming hormone treatment. The goal is to understand how the treatment influences heart health and cardiovascular risk over time. Participants will receive standard feminizing hormone treatment as part of the study. The follow-up will occur at 1 year, 3 years, 5 years, and 10 years after starting treatment. Researchers will monitor cardiovascular outcomes including coronary plaque formation, heart function using echocardiograms, and various cardiovascular risk markers measured in blood and urine. Throughout the study, participants will undergo coronary CT angiograms to assess plaque development and echocardiograms to evaluate heart function. Blood pressure and other cardiovascular risk markers will also be checked periodically. The main outcome measured is coronary plaque formation after 1 year, with longer-term cardiovascular effects observed during extended follow-ups. The total duration of participation may last up to 10 years.
CONDITIONS
Brief Title
Feminizing Treatment in Transgender Women and Non-binary Persons
Research Team
D
Dorte Glintborg
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
